Australia HIV Therapeutics Market Analysis Report [2022-30] I Insights10

Australia HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Australia HIV therapeutics market will reach a value of $229.48 Mn from $165.12 Mn in 2022, growing at a CAGR of 4.2% during 2022-2030. The market is primarily dominated by local players such as Bionomics, Prima Biomed and Imugene Limited. The market is driven by innovation in research and development, increasing prevalence, and government funding policies. The HIV therapeutics market in Australia is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10AUPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Dr. Vishwa Modhia

Buy Now

Australia HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Australia HIV therapeutics market will reach a value of $229.48 Mn from $165.12 Mn in 2022, growing at a CAGR of 4.2% during 2022-2030.

In Australia, the adult prevalence rate of HIV/AIDS was predicted to be 0.1% in 2021. In Australia, 29,460 people with HIV were projected to exist in 2021. By the end of 2021, approximately 91% of these individuals had received a diagnosis. The study also reveals that 92% of those with HIV diagnoses were receiving treatment, and 98% of those receiving treatment had viral loads that were undetectable.

60% of HIV notifications in 2021 were attributed to male-to-male sexual contact. A total of 27% of cases were linked to heterosexual sex, 8% to male-on-male sexual contact combined with injecting drug use, 2% to injecting drug use by itself, and 3% to other/unspecified causes.

The Australian government has taken significant steps to fight the HIV/AIDS epidemic in the nation, including offering free antiretroviral therapy (ART) to those who qualify through the Medicare public healthcare program. The Australian government also contributes financially to the private sector's efforts to combat HIV/AIDS. Australia's 2019 health spending as a percentage of GDP is 9.9%.

australia HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

The highest per capita number of PrEP users worldwide in 2021 was found in Australia, where more than 38,000 people had access to it. This represents a potential source of growth for the Australian HIV therapeutics market. HIV treatment long-acting injectables became accessible in 2021. People have the option of choosing one injection every two months in place of one pill a day.

Continual funding for community-based HIV organizations nationally coordinated health promotion efforts, and local implementation through AFAO members are all crucial aspects in Australia.

Market Restraints

Access to HIV/AIDS treatment is still difficult in Australia despite government efforts, especially for marginalized groups like transgender people, people who inject drugs, and people who have sex with other men.

Competitive Landscape

Key Players

CSL Limited (AUS)
Bionomics (AUS)
Starpharma (AUS)
Vical (AUS)
Prima Biomed (AUS)
Imugene Limited (AUS)
GlaxoSmithKline
Janssen Pharmaceuticals
Gilead

Healthcare Policies and Reimbursement Scenarios

The Australian Federation of AIDS Organizations (AFAO), the leading national body for Australia's community HIV response, is renowned both abroad and at home for its leadership, expertise in public policy, dedication to health promotion, coordination, and support. In Australia, there are many different ways to pay for healthcare services, including Medicare, the Pharmaceutical Benefits Scheme (PBS), hospital funding, and aged care.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.